• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GLIMEPIRIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • GLIMEPIRIDE chembl:CHEMBL1481 ApprovedImmunotherapy

    Alternate Names:

    AMARYL
    HOE-490
    GLIMEPIRIDE
    NIDDARYL

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidiabetic
    Year of Approval 1995
    Drug Class hypoglycemic agents
    (4 More Sources)

    Publications:

    Müller et al., 1994, Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics., Biochim. Biophys. Acta
    Kramer et al., 1995, The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels., Diabetes Res. Clin. Pract.
    Kramer et al., 1996, Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells., Horm. Metab. Res.
    Li Q et al., 2014, KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol
    Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
    Javorsky M et al., 2012, KCNJ11 gene E23K variant and therapeutic response to sulfonylureas., Eur J Intern Med
    Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
    Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med
    Lawrence et al., 2002, Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels., Br. J. Pharmacol.
    Song et al., 2001, Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels., Br. J. Pharmacol.
    Bataille, 2002, [Molecular mechanisms of insulin secretion]., Diabetes Metab.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Proks et al., 2002, Sulfonylurea stimulation of insulin secretion., Diabetes
    Müller et al., 2005, Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C in rat adipocytes., Biochem. Pharmacol.
    Niemi M et al., 2002, Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes., Clin Pharmacol Ther
    Suzuki K et al., 2006, Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes., Diabetes Res Clin Pract
    Mori et al., 2004, Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity., Diabetes Obes Metab
  • GLIMEPIRIDE   KCNJ11

    Interaction Score: 3.59

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Sulfonylurea receptor 1, Kir6.2 blocker
    Direct Interaction yes
    Trial Name glimepiride,Amaryl

    PMIDs:
    25115353 24442125 22385882 16595597 11318841 12086984 11325810 12703060


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB

  • GLIMEPIRIDE   KCNJ1

    Interaction Score: 3.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name rosiglitazone + glimepiride,Avandaryl
    Novel drug target Established target
    Trial Name glimepiride ,Amaryl

    PMIDs:
    17016423 17139284 12703060 12475777


    Sources:
    TdgClinicalTrial TEND

  • GLIMEPIRIDE   ABCC8

    Interaction Score: 2.73

    Interaction Types & Directionality:
    blocker (inhibitory)
    inducer (activating)

    Interaction Info:
    Trial Name glimepiride,Amaryl
    Novel drug target Established target
    Trial Name rosiglitazone + glimepiride,Avandaryl

    PMIDs:
    8172912 8529521 8911984


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • GLIMEPIRIDE   IRS1

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15710354


    Sources:
    NCI

  • GLIMEPIRIDE   ABCC9

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • GLIMEPIRIDE   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14686960


    Sources:
    NCI

  • GLIMEPIRIDE   G6PD

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • GLIMEPIRIDE   CYP2C9

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24442125 12235454 16325295


    Sources:
    PharmGKB

  • TEND: GLIMEPIRIDE

    • Version: 01-August-2011

    Alternate Names:
    GLIMEPIRIDE Primary Drug Name

    Drug Info:
    Drug Class hypoglycemic agents
    Year of Approval 1995

    Publications:

  • TdgClinicalTrial: GLIMEPIRIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: GLIMEPIRIDE

    • Version: 14-September-2017

    Alternate Names:
    C29073 NCI drug code

    Drug Info:

    Publications:
    Lawrence et al., 2002, Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels., Br. J. Pharmacol.
    Mori et al., 2004, Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity., Diabetes Obes Metab
    Müller et al., 2005, Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C in rat adipocytes., Biochem. Pharmacol.

  • PharmGKB: glimepiride

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
    Niemi M et al., 2002, Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes., Clin Pharmacol Ther
    Suzuki K et al., 2006, Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes., Diabetes Res Clin Pract

  • TTD: Glimepiride

    • Version: 2020.06.01

    Alternate Names:
    D0B2GI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1481

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1481

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Glimepiride

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21